Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
RNA immunotherapies targeting novel tumour-specific antigens
Epitopea is a biopharma company developing off-the-shelf RNA-based immunotherapies for hard-to-treat cancers. Using spatial immunopeptidomics, genomics, and systems bioinformatics, the company identifies aberrantly-expressed tumour-specific antigens that are broadly shared across patients with the same tumour type.…
Gene therapy biotech targeting neural circuit dysfunction
Sania Therapeutics is a biotechnology company developing genetic medicines for diseases caused by dysfunctional neural circuits. Its approach combines precision AAV delivery to selected neural circuits with tuneable neuromodulation, using human iPSC-derived neural models to direct the evolution of human-centric…
Clinical-stage biopharma developing treatments for cancer and rare diseases
Biodexa Pharmaceuticals is a Cardiff-based clinical-stage biopharmaceutical company advancing a pipeline of proprietary drug formulations for diseases with high unmet need. Its lead programme, eRapa, an encapsulated oral formulation of rapamycin, is in a Phase 3 registrational trial for familial adenomatous polyposis,…
Non-viral intracellular drug delivery for solid tumours
Vitarka Therapeutics is a preclinical biotech company developing a non-viral drug delivery platform for targeted intracellular delivery of therapeutics to solid tumours. The technology uses pore-forming proteins to transport RNAi therapies and other payloads directly into cancer cells while limiting off-target…
Approved presbyopia eye drops and investigational retinal therapies
Tenpoint Therapeutics is an ophthalmic biopharmaceutical company developing medicines and regenerative cell therapies for age-related vision disorders. Its dual-agent carbachol/brimonidine eye drops received US FDA approval for presbyopia in January 2026 and became commercially available in March. A UK regulatory…
Small activating RNA therapeutics for gene upregulation and disease
MiNA Therapeutics is a clinical-stage biotechnology company pioneering small activating RNA medicines, a class of oligonucleotide therapeutics that restore or boost expression of underactive genes by activating transcription rather than silencing it. The approach targets diseases driven by loss of normal gene…
Cocrystal drug repurposing for oncology supportive care and fibrosis
Nuformix is a pharmaceutical development company using proprietary cocrystal technology to repurpose existing drugs for unmet medical needs in fibrosis and oncology. By reengineering a drug's crystal form, the company improves properties such as dissolution and absorption, creating differentiated, patentable products…
Herpesvirus-vectored vaccines for livestock and companion animals
The Vaccine Group develops recombinant herpesvirus-vectored vaccines against infectious diseases affecting livestock and companion animals. Its modular platform is designed to generate durable immune responses in young animals, including those carrying maternally derived antibodies. Development programmes include…
Bispecific antibody-drug conjugates for hard-to-treat solid tumours
Valink Therapeutics is a biotechnology company developing next-generation bispecific antibody-drug conjugates and multispecific antibody therapeutics for oncology. Its proprietary discovery platform enables modular assembly of complex antibody formats combining multispecificity, multivalency, and drug conjugation,…
Global pharma company in oncology, immunology, and neuroscience
Johnson & Johnson is a multinational pharmaceutical company with UK operations spanning commercial, medical affairs, and innovation activities. Its Innovative Medicine division covers oncology, immunology, neuroscience, and infectious disease. The company operates an EMEA Innovation Centre in London focused on…
AI-designed extended-expression RNA therapeutics for cardio-metabolic disease
ScionxBio, formerly Eleven Therapeutics, is a biotechnology company developing xRNA, a chemically expanded RNA modality engineered to extend protein expression from days to months. Combinatorial chemistry and deep learning are combined to design molecules with enhanced stability and reduced immune sensing, enabling…
Dendritic cell biology platform for cancer and autoimmune therapies
Adendra Therapeutics is a discovery-stage biotechnology company developing small molecule and biologic medicines targeting dendritic cell biology for the treatment of solid tumours and autoimmune diseases. The company's approach is based on research into how dendritic cells regulate adaptive immune responses to cell…
AI-powered drug design engine built on AlphaFold technology
Isomorphic Labs is an artificial intelligence company applying frontier AI to drug discovery, built on and beyond the Nobel Prize-winning AlphaFold protein structure prediction system developed at Google DeepMind. Its proprietary drug design engine spans target identification, molecular design, and binding prediction…
Gene therapy company targeting inherited and degenerative diseases
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company developing AAV-based gene therapies for inherited retinal diseases, neurodegenerative conditions, and salivary gland disorders. The company operates end-to-end capabilities spanning viral vector design, GMP manufacturing, and clinical…
Regenerative cell therapy for sensorineural hearing loss
Rinri Therapeutics is a clinical-stage biotech developing allogeneic regenerative cell therapies for sensorineural hearing loss, a condition affecting over 400 million people worldwide for which no disease-modifying treatment currently exists. Its lead programme, Rincell-1, is an otic neural progenitor cell therapy…
G-quadruplex-targeting medicines for precision cancer treatment
Genome Therapeutics is a biotechnology company developing cancer medicines that target G-quadruplex DNA structures associated with tumour biology. Its approach builds on research into non-canonical DNA folding and how these structures influence gene regulation and cancer cell vulnerabilities. The company develops…
Small molecule drugs targeting astrocytes in neurodegenerative disease
AstronauTx is a clinical-stage UK biotech developing oral small molecule therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's approach targets astrocytes, brain support cells whose dysregulated inflammatory activity contributes to neurodegeneration, aiming to restore normal…
Structure-guided small-molecule therapeutics for antiviral and metabolic diseases
Halo Therapeutics is a University of Bristol spinout developing structure-guided small-molecule medicines for infectious and metabolic diseases. Its research combines cryo-electron microscopy, protein biophysics and computational chemistry to identify drug-binding pockets and design selective compounds. Its antiviral…
Global generics and specialty pharmaceutical manufacturer headquartered in London
Hikma Pharmaceuticals is a multinational pharmaceutical company developing, manufacturing and marketing generic, specialty and branded medicines across injectable, oral and respiratory dosage forms. The company's portfolio spans oncology, cardiovascular, respiratory, pain management and other therapeutic areas,…
Small molecule therapies for cystic fibrosis and COPD
Enterprise Therapeutics is a clinical-stage biopharmaceutical company developing novel muco-regulatory therapies for respiratory diseases. Its lead programme ETD001 is a first-in-class inhaled ENaC blocker designed to hydrate airway mucus and improve mucociliary clearance, currently in a Phase 2a trial in cystic…